menu search

Amgen to buy horizon therapeutics for $116.50 per share

Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rar...

December 12, 2022, 8:11 am

Roche names new ceo with schwan set to become chairman

Roche has appointed Thomas Schinecker as the new group chief executive, the company said on Monday, replacing Severin Schwan who the ...

December 12, 2022, 1:32 am

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Bellicum announces presentation by unc at ash 2022 on potential abrogation of ic9 car t-cell toxicities with rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in ...

December 11, 2022, 3:00 pm

Eli lilly: what to do when the market doesn't care about valuation

LLY is one of the best performing pharmaceutical stocks in 2022 and has reached a $340 billion market c...

December 11, 2022, 2:35 am

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm


Search within

Pages Search Results: